Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractoy Mantle Cell Lymphoma.

Trial Profile

Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractoy Mantle Cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 20 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 04 Dec 2011 United Kingdom Clinical Research Network reports accrual to date changed from 32 to 35%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top